Research and Markets: Examine the Top 20 Companies in Late and Early Stage of Glaucoma Projects Inside ''Ophthalmology and Optometry - Glaucoma Drug Pipeline Report''
Posted on: Wednesday, 11 July 2007, 15:05 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c62316) has announced the addition of Ophthalmology and Optometry - Glaucoma Drug Pipeline Report to their offering.
"Ophthalmology and Optometry - Glaucoma Drug Pipeline Report" contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of glaucoma drugs by company and by stage as well as a summary of the latest news and developments in this area.
Scope of the report:
Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.
In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company's full product pipeline and products by phase of development with regard to the therapy area.
Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides details on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.
Key benefits
- Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
- Keep track of your competitors and partners by better understanding their product pipeline.
- Monitor a company's research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
- Maintain a critical competitive advantage.
Content Outline:
UPCOMING PATENT EXPIRES BY THERAPY AREA
Glaucoma Pipeline Overview
--% of Projects (By Phase of Development)
--No. of Projects by Phase of Development
--Marketed Products Vs. Pipeline Products
Company Overview - Pipeline Projects
--Company Overview - Pipeline Projects
--Legend
--Top 20 companies in late stage Glaucoma Projects
--Top 20 companies in early stage Glaucoma Projects
Full Pipeline View
--Pre Clinical Pipeline View
--Phase I Pipeline View
--Phase II Pipeline View
--Phase III Pipeline View
--Pending Approval Pipeline View
For more information visit http://www.researchandmarkets.com/reports/c62316.
Source: Life Science Analytics
Source: Business Wire
Related Articles
- Pima County, Arizona Contracts with Motorola to Provide Project 25 Phase 2 TDMA
- Noble Energy Starts Production From Second Phase of Dumbarton Development
- VIRxSYS Presents New VRX496 Phase II HIV Gene Therapy Trial Data
- Energy, Refining and Pipeline Construction Projects Push Wisconsin Industrial Development to $14.6 Billion, an Industrial Info News Alert
- Heartland Oil and Gas Continues Production Enhancement and Well and Pipeline Expansion Projects in Texas and Kansas
- Targacept Announces Initiation of Phase IIb Development of AZD3480 (TC-1734) for Alzheimer's Disease
- ACADIA Announces Positive Results From ACP-103 Phase II Schizophrenia Co-Therapy Trial
- Energy Transfer Partners, L.P. Announces Completion of First Phase of 42-Inch Pipeline Expansion Project
- AGTC and JDRF Announce Partnership to Develop Gene Therapy for Diabetic Eye Disease
 |
 |
User Comments (0)
RSS Feeds